Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study.
Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Harary E, Alexander J, Barkay H, Gordon MF. Jankovic J, et al. Among authors: alexander j. Mov Disord Clin Pract. 2023 Aug 24;10(9):1388-1398. doi: 10.1002/mdc3.13849. eCollection 2023 Sep. Mov Disord Clin Pract. 2023. PMID: 37772282 Free PMC article.
On crushing of deutetrabenazine tablets.
Knebel H, Alexander J, Wilhelm A, Loupe P, Schneider F, Gordon MF. Knebel H, et al. Among authors: alexander j. Am J Health Syst Pharm. 2021 Aug 30;78(17):1551-1552. doi: 10.1093/ajhp/zxab130. Am J Health Syst Pharm. 2021. PMID: 33821933 Free PMC article. No abstract available.
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Gordon MF, Alexander J, Barkay H, Harary E. Jankovic J, et al. Among authors: alexander j. JAMA Netw Open. 2021 Oct 1;4(10):e2128204. doi: 10.1001/jamanetworkopen.2021.28204. JAMA Netw Open. 2021. PMID: 34609495 Free PMC article. Clinical Trial.
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
Coffey B, Jankovic J, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Gordon MF, Alexander JK, Barkay H, Harary E. Coffey B, et al. Among authors: alexander jk. JAMA Netw Open. 2021 Oct 1;4(10):e2129397. doi: 10.1001/jamanetworkopen.2021.29397. JAMA Netw Open. 2021. PMID: 34661664 Free PMC article. Clinical Trial.
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
Hauser RA, Barkay H, Fernandez HH, Factor SA, Jimenez-Shahed J, Gross N, Marinelli L, Wilhelm A, Alexander J, Gordon MF, Savola JM, Anderson KE. Hauser RA, et al. Among authors: alexander j. Front Neurol. 2022 Feb 23;13:773999. doi: 10.3389/fneur.2022.773999. eCollection 2022. Front Neurol. 2022. PMID: 35280262 Free PMC article.
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M. Frank S, et al. Among authors: alexander jk. Neurol Ther. 2024 Jun;13(3):655-675. doi: 10.1007/s40120-024-00600-1. Epub 2024 Apr 1. Neurol Ther. 2024. PMID: 38557959 Free PMC article.
Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M. Frank S, et al. Among authors: alexander jk. Neurol Ther. 2024 Dec;13(6):1747-1749. doi: 10.1007/s40120-024-00660-3. Neurol Ther. 2024. PMID: 39266813 Free PMC article. No abstract available.
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study.
Rieckmann P, Zivadinov R, Boyko A, Selmaj K, Alexander JK, Kadosh S, Rubinchick S, Bernstein-Hanlon E, Stark Y, Ashtamker N, Davis MD, Khan O. Rieckmann P, et al. Mult Scler J Exp Transl Clin. 2021 Dec 13;7(4):20552173211061550. doi: 10.1177/20552173211061550. eCollection 2021 Oct. Mult Scler J Exp Transl Clin. 2021. PMID: 34925876 Free PMC article.
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Ford CC, Cohen JA, Goodman AD, Lindsey JW, Lisak RP, Luzzio C, Pruitt A, Rose J, Rus H, Wolinsky JS, Kadosh SE, Bernstein-Hanlon E, Stark Y, Alexander JK. Ford CC, et al. Among authors: alexander jk. Mult Scler. 2022 Oct;28(11):1729-1743. doi: 10.1177/13524585221094239. Epub 2022 Jun 29. Mult Scler. 2022. PMID: 35768939 Free PMC article. Clinical Trial.
6,168 results